All my previous posts have been related to the market and financial aspects of the pharma and biotech industry. In this post, I am focusing on the human resources aspects and why Biotech is different. Biotech can be categorised as large biotech or big pharma (Novartis, Amgen, Biotech, Celgene and the like) and smaller biotech […]
Tag: biotechnology
The methodology for valuing biotech products using the risk-adjusted NPV (‘rNPV’) approach has been well established. The concept behind the rNPV method is taking into account the risk of success / failure in clinical trials for clinical development products. In this way, companies can prioritise their portfolio based on the expected value of each product. […]